← Back to Home

BioMarin licenses Fabry disease drug candidate for up to $475 million, targeting subcutaneous treatment

This long-acting enzyme replacement therapy aims to make enzyme supplementation more convenient and is currently in a Phase 1/2 trial. The deal adds resources for development, but whether it can combine convenient administration with organ protection remains a question for human data to answer.

By SURL BioNews

For people with Fabry disease, the burden of treatment comes not only from the disease itself but also from repeatedly replenishing an enzyme their bodies lack. A long-acting drug candidate being developed for subcutaneous injection has now gained new momentum: on October 29, BioMarin announced that it had acquired exclusive development and commercialization rights outside South Korea to HM15421/GC1134A from South Korea’s GC Biopharma and Hanmi Pharm.

BioMarin will pay $70 million upfront, with up to an additional $405 million in development and commercial milestone payments, as well as tiered royalties based on net sales. An announcement released by GC Biopharma the following day also confirmed the arrangement. The reported deal value of up to $475 million therefore includes payments contingent on meeting conditions, rather than an amount paid in full at signing.

Fabry disease is an inherited lysosomal storage disorder. Variants in the GLA gene cause insufficient activity of α-galactosidase A, allowing lipids that would normally be broken down to gradually accumulate, potentially damaging the kidneys, heart, and nerves. The basic idea behind enzyme replacement therapy is to replenish the missing enzyme; development of this candidate focuses on keeping the enzyme in the body longer and supporting subcutaneous administration.

HM15421/GC1134A, also known as LA-GLA, combines Hanmi Pharm’s long-acting drug platform with GC Biopharma’s experience in enzyme replacement therapy manufacturing and clinical development. According to announcements from the two companies and reporting by ChosunBiz, its design focuses on extending half-life and improving stability. If an appropriate dose and method of administration can be established in humans, it could ease the burden of treatment scheduling; this does not currently establish that patients can inject it themselves at home or that a dosing interval has been determined.

The program is currently in a global Phase 1/2 clinical trial. Under the agreement, after the current trial ends, BioMarin will take over subsequent clinical development, manufacturing, and commercialization outside South Korea, while GC Biopharma and Hanmi Pharm will retain regulatory and commercialization responsibilities for the South Korean market. For BioMarin, this also extends its Fabry disease strategy following its acquisition of Amicus, exploring treatment opportunities beyond the range of gene variants eligible for the existing drug Galafold.

As for efficacy, the findings related to kidney function, blood vessels, and peripheral nerves mentioned in BioMarin’s announcement and ChosunBiz’s reporting all come from preclinical studies and cannot be directly interpreted as evidence of organ protection in patients. The deal did not provide complete data sufficient to assess efficacy in humans; although the drug received orphan drug designation from the U.S. FDA in 2024, that designation does not equate to marketing approval. The licensing deal establishes the division of responsibilities for further development, while clinical trials must still verify whether subcutaneous injection can deliver sustained and safe therapeutic benefits.

References

  1. BioMarin Pharmaceutical
  2. GC Biopharma via Korea Newswire
  3. ChosunBiz